ASCO 2018 Annual Meeting Highlights in Multiple Myeloma


ASCO Overview from Saad Z. Usmani, MD, FACP
– Run Time: 7:47

Begin


ASCO Highlights from Noopur Raje, MD
  • bb2121 anti-BCMA CAR T cell therapy in RRMM
  • Ex vivo expanded cord blood natural killer cells
  • FDA analysis of pembrolizumab trials
Run Time: 9:56

Begin


ASCO Highlights from Sagar Lonial, MD, FACP
  • Phase 2 study: Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in RRMM
  • 5-year follow-up phase 3 ELOQUENT-2 (elotuzumab/lenalidomide/dex vs len/dex) in RRMM
  • ALCYONE: Daratumumab plus bortezomib-melphalan-prednisone
  • Phase 3 AQUILA: Subcutaneous daratumumab vs active monitoring in high-risk SMM
Run time: 5:44

Begin


ASCO Highlights from Saad Z. Usmani, MD, FACP
  • Pembrolizumab plus lenalidomide/dexamethasone vs len/dex for NDMM: KEYNOTE-185
  • Subcutaneous daratumumab in RRMM: Dose escalation phase 1b PAVO
  • COLUMBA phase 3 study: Subcutaneous vs IV daratumumab in RRMM
  • Phase Ib results: Isatuximab plus pomalidomide/dex in RRMM
  • Pomalidomide/bortezomib/dex vs bortezomib/dex in RRMM: Phase 3 OPTIMISMM trial
Run time: 7:45

Begin


ASCO Highlights from Robert Z. Orlowski, MD, PhD
  • Carfilzomib/dexamethasone vs bortezomib/dex RRMM: ENDEAVOR update
  • Phase 3 IKEMA: Isatuximab/carfilzomib/dex vs carfilzomib/dex in RRMM
  • Phase 3 IMROZ: Isatuximab/bortezomib/len/dex vs bortezomib/len/dex in NDMM
Run Time: 6:15

Begin